EMA Aesthetics signs agreement with 4ocean to become ‘plastics neutral’.
DUBLIN, Nov. 7, 2022 /PRNewswire/ -- EMA Aesthetics (www.emaaesthetics.com), an international aesthetics company headquartered in Dublin, announces its collaboration with 4ocean, the ocean cleanup company that's on a mission to end the world's ocean plastic crisis. The goal of EMA Aesthetics participation in 4ocean's Certified Cleanup Partnership Program is to become plastics neutral across...
Hexvix®, A Diagnostic Drug for Bladder Cancer of Asieris, Completed the First Patient Dose in Phase III Trial
SHANGHAI, Nov. 7, 2022 /PRNewswire/ -- Asieris Pharmaceuticals, a global biopharmaceutical company specializing in the discovery and development of innovative drugs for the treatment of genitourinary tumors and other major diseases, announced that Hexvix®, a drug used for the diagnosis for bladder cancer, completed the first patient dose in Phase III bridging trial. The study is a prospective, self-controlled,...
Ascletis Announces Poster Presentation of Phase I, Single-Dose Study of ASC43F for NASH at AASLD Annual Meeting 2022
HANGZHOU and SHAOXING, China, Nov. 7, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces today that the abstract of a Phase I, Single-Dose Study of ASC43F for non-alcoholic steatohepatitis (NASH) has been reported at The Liver Meeting® 2022 of the American Association for the Study of Liver Diseases (AASLD) as poster presentation. The summary of the abstract is...
Innovent Releases Results of a Phase 3 Clinical Study of Tafolecimab（IBI306）in Chinese Patients with non- Familial Hypercholesterolemia at the American Heart Association (AHA) Scirntific Sessions 2022
ROCKVILLE, M.D. and SUZHOU, China, Nov 7, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announces that the results of a phase 3 clinical study (CREDIT-1) of tafolecimab (IBI306), a recombinant fully human anti-PCSK-9 monoclonal antibody,...
Herbalife Nutrition Survey: Unbalanced Diet, Physical Inactivity and Inadequate Sleep Among the Top Unhealthy Habits APAC Consumers Want to Kick in Next 12 Months
Virtual Run by Herbalife Nutrition is back for the third year running to spur actions for building healthy active living habits among Asia Pacific consumers SYDNEY, Nov. 7, 2022 /PRNewswire/ -- Premier global nutrition company, Herbalife Nutrition released the findings from its Asia Pacific Personal Habits Survey today, revealing that 8 out of ten consumers in the APAC region...
Brexogen’s Exosome Therapy for Atopic Dermatitis, ‘BRE-AD01’ Accepted for Phase 1 Clinical Trials by US FDA
First entry to clinical trial of exosome for atopic dermatitis The first exosome-based therapeutics in US clinical trial among Korean companies SEOUL, South Korea, Nov. 7, 2022 /PRNewswire/ -- The US FDA granted the initiation of the phase 1 clinical trial of 'BRE-AD01', an exosome- based therapy for atopic dermatitis. 'BRE-AD01'...
Telix Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study
Summary of Study Outcomes ZIRCON Phase III study of Telix's investigational imaging agent TLX250-CDx in clear cell renal cell carcinoma (ccRCC) has met all of its primary and secondary endpoints The study delivered co-primary endpoints of 86% sensitivity and 87% specificity and 93% positive predictive value (secondary endpoint) considerably exceeding sensitivity...
ZEISS Makes Fifth Appearance at CIIE, Placing Great Effort in Localization Strategy
SHANGHAI, Nov. 6, 2022 /PRNewswire/ -- The fifth China International Import Expo (CIIE) is currently under way at National Exhibition and Convention Center. ZEISS, a global leader in optics and optoelectronics, is making its fifth appearance in this year's CIIE, showcasing its products at Booth B4-01 in Hall 4.1 with a theme of "A Heart for Science". Innovative products...
China Marches into the Era of Interventional Direct Annuloplasty
Launching of the 1st Human Implantation of "DragonRing" – Catheter-based Mitral Annuloplasty Device HANGZHOU, China, Nov. 6, 2022 /PRNewswire/ -- On October 28, 2022, a multidisciplinary, and international cardiac team led by Professor Mao Chen from Department of Cardiology, West China Hospital, Sichuan University, successfully performed the world's first human implantation of "DragonRing", which is the first interventional transfemoral...
TurtleTree to Represent Singapore at UN Climate Change Conference 2022 as Official Drink Partner
SHARM EL-SHEIKH, Egypt and SINGAPORE, Nov. 5, 2022 /PRNewswire/ -- TurtleTree will be Singapore's official drink partner at this year's UN Climate Change Conference (COP27), taking place from 6 to 18 November in Sharm El-Sheikh, Egypt. Acting in collaboration with the Prime Minister's Office of Singapore, TurtleTree's participation at the event will see the company serve...
